GSK says tests show Vir antibody drug works against Omicron
GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based COVID-19 therapy it is developing with U.S. partner Vir has indicated that the drug also works against the new Omicron variant.
Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.
ALSO READ
-
Ceasefire Stalled: U.S., Iran Diplomatic Efforts Falter Amid Rising Tensions
-
Stalemate in U.S.-Iran Tensions: Diplomatic Efforts Falter
-
Security Tightens Ahead of King's U.S. Visit Amid Shooting Incident
-
Deadlock in Diplomacy: Struggles in U.S.-Iran Conflict Resolution
-
Detained Again: An Egyptian Family's Struggle in U.S. Immigration System
Google News